Reviewing Cellular Biomedicine Group Inc. (CBMG)’s and VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s results – MS Wkly

By daniellenierenberg

We are contrasting Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Table 1 showcases the gross revenue, earnings per share and valuation of Cellular Biomedicine Group Inc. and VistaGen Therapeutics Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Volatility & Risk

Cellular Biomedicine Group Inc. is 167.00% more volatile than Standard & Poors 500 because the company has a beta of 2.67. In other hand, VistaGen Therapeutics Inc. has beta of -0.48 which is 148.00% less volatile than Standard & Poors 500.

Liquidity

Cellular Biomedicine Group Inc. has a Current Ratio of 4.4 and a Quick Ratio of 4.4. Competitively, VistaGen Therapeutics Inc.s Current Ratio is 4.9 and has 4.9 Quick Ratio. VistaGen Therapeutics Inc.s better ability to pay short and long-term obligations than Cellular Biomedicine Group Inc.

Analyst Ratings

The table given features the ratings and recommendations for Cellular Biomedicine Group Inc. and VistaGen Therapeutics Inc.

Cellular Biomedicine Group Inc. has a 55.30% upside potential and an average target price of $23. Competitively VistaGen Therapeutics Inc. has an average target price of $22, with potential upside of 1,592.31%. The results from earlier shows that analysts opinion suggest that VistaGen Therapeutics Inc. seems more appealing than Cellular Biomedicine Group Inc.

Institutional & Insider Ownership

Institutional investors held 23.8% of Cellular Biomedicine Group Inc. shares and 20.4% of VistaGen Therapeutics Inc. shares. Insiders held roughly 37.14% of Cellular Biomedicine Group Inc.s shares. Competitively, insiders own roughly 0.2% of VistaGen Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Cellular Biomedicine Group Inc. has stronger performance than VistaGen Therapeutics Inc.

Summary

On 6 of the 11 factors VistaGen Therapeutics Inc. beats Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more here:
Reviewing Cellular Biomedicine Group Inc. (CBMG)'s and VistaGen Therapeutics Inc. (NASDAQ:VTGN)'s results - MS Wkly

Related Post


categoriaCardiac Stem Cells commentoComments Off on Reviewing Cellular Biomedicine Group Inc. (CBMG)’s and VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s results – MS Wkly | dataOctober 18th, 2019

About...

This author published 1116 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research